Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin and Hodgkin).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Lenalidomide (lenalidomide)
• nivolumab (nivolumab)

Snippet

Sponsor: David Bond, MD | Conditions: Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING